Rockwell Medical (RMTI) Proxy filing summary

Executive summary

• Supplemental proxy materials address a critical reverse stock split proposal for the 2026 Annual Meeting.

• The reverse stock split is intended to help regain compliance with Nasdaq's minimum bid price requirement.

• Nasdaq notified the company on May 8, 2026, of non-compliance with the $1.00 minimum bid price rule.

• The company has until November 4, 2026, to regain compliance, or risk delisting from Nasdaq.

• Forward-looking statements caution that there is no assurance of regaining or maintaining compliance.

Voting matters and shareholder proposals

• Proposal 4 seeks shareholder approval to effect a reverse stock split at the 2026 Annual Meeting.

• The Board recommends voting in favor of the reverse stock split to address Nasdaq compliance.

Risk oversight and compliance

• Failure to meet the minimum bid price for 30 consecutive business days triggered the Nasdaq notice.

• The company will remain listed during a 180-day grace period to regain compliance.

• If compliance is not achieved by November 4, 2026, additional time may be sought, but is not guaranteed.

• Risks include potential delisting and uncertainty regarding the effectiveness of the reverse stock split.